




Part II: Statistical Inference

Lieven Clement


Proteomics Data Analysis Shortcourse



Statistical Inference

- Francisella tularensis Example
- O Hypothesis testing
- Multiple testing
- Moderated statistics
- Experimental design


Francisella tularensis experiment



• Pathogen: causes tularemia

Data

- Metabolic adaptation key for intracellular life cycle of pathogenic microorganisms.
- Upon entry into host cells quick phasomal escape and active multiplication in cytosolic compartment.
- Francisella is auxotroph for several amino acids, including arginine.
- Inactivation of arginine transporter delayed bacterial phagosomal escape and intracellular multiplication.
- Experiment to assess difference in proteome using 3 WT vs 3 ArgP KO mutants




∢ *⊟* → 4/33 Summarized data structure


- WT vs KO
- 3 vs 3 repeats
- 882 proteins

Protein	WT_1	WT_2	WT ₃	KO1	KO ₂	KO ₃
gi 118496616	29.83	29.77	29.91	29.70	29.86	29.80
gi 118496617	31.28	31.23	31.51	31.30	31.51	31.76
gi 118496635	32.39	32.27	32.24	32.25	32.14	32.22
gi 118496636	30.74	30.54	30.64	30.65	30.49	30.60
gi 118496637	29.56	29.35	29.56	29.30	29.24	29.14
gi 118498323	31.38	30.52	30.62	31.04	27.38	NA
:	÷	÷	÷	÷	:	÷

T-test

Hypothesis testing: a single protein






If we can assume equal variance in both treatment groups:

$$\operatorname{se}_{\Delta} = \operatorname{SD}_{\sqrt{\frac{1}{n_1} + \frac{1}{n_2}}}$$

T-test

Hypothesis testing: a single protein



Francisella (gi|118497015)

$$t = \frac{\log_2 \widehat{\mathsf{FC}}}{\mathsf{se}_{\log_2 \widehat{\mathsf{FC}}}} = \frac{-1.4}{0.118} = -11.9$$

Is t = -11.9 indicating that there is an effect?

How likely is it to observe t = -11.8 when there is no effect of the argP KO on the protein expression?

H_0 vs H_1

Null hypothesis and alternative hypothesis

- In general we start from alternative hypothese H_A : we want to show an effect of the KO on a protein
 - On average the protein abundance in WT is different from that in KO

Null hypothesis and alternative hypothesis

- In general we start from **alternative hypothese** *H*_A: we want to show an effect of the KO on a protein
 - On average the protein abundance in WT is different from that in KO
- But, we will assess it by falsifying the opposite: **null hypothesis** *H*₀
 - $\bullet\,$ On average the protein abundance in WT is equal to that in KO

Data H_0 vs H_1


```
Two Sample t-test
```

```
data: z by treat
t = -11.449, df = 4, p-value = 0.0003322
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-1.031371 -1.691774
sample estimates:
mean in group D8 mean in group WT
29.26094 30.62251
```

- How likely is it to observe an equal or more extreme effect than the one observed in the sample when the null hypothesis is true?
- When we make assumptions about the distribution of our test statistic we can quantify this probability: **p-value**. The p-value will only be calculated correctly if the underlying assumptions hold!
- When we repeat the experiment, the probability to observe a fold change more extreme than a 2.6 fold ($\log_2 FC = -1.36$) down or up regulation by random change (if H_0 is true) is 3 out of 10.000.
- If the p-value is below a significance threshold α we reject the null hypothesis. We control the probability on a false positive result at the α -level (type I error)

H_0 vs H_1

Hypothesis testing: a single protein



Multiple hypothesis testing

Problem of multiple hypothesis testing

- Consider testing DA for all m = 882 proteins simultaneously
- What if we assess each individual test at level α ?
- $\rightarrow\,$ Probability to have a false positive among all $\,m$ simultatenous test >>> $\,\alpha=0.05$


Suppose that 600 proteins are non-DA, then we could expect to discover on average $600 \times 0.05 = 30$ false positive proteins. Hence, we are bound to call false positive proteins each time we run the experiment.

FDR: False discovery rate

- FDR: Expected proportion of false positives on the total number of positives you return.
- An FDR of 1% means that on average we expect 1% false positive proteins in the list of proteins that are called significant.
- Defined by Benjamini and Hochberg in 1995

$$\mathsf{FDR}(|t_{\mathsf{thres}}|) = \mathsf{E}\left[\frac{FP}{FP + TP}\right] = \frac{\pi_0 Pr(|T| \ge t_{\mathsf{thres}}|H_0)}{Pr(|T| \ge t_{\mathsf{thres}})}$$
$$\mathsf{FDR}_{\mathsf{BH}}(|t_{\mathsf{thres}}|) = \frac{1 \times p_{t_{\mathsf{thres}}}}{\frac{\#|t_i| \ge t_{\mathsf{thres}}}{m}}$$

• FDR adjusted p-values can be calculated (e.g. Perseus, R, ...)




Ordinary t-test

Moderated Statistics


Problems with ordinary t-test






Ordinary t-test


Problems with ordinary t-test



Original t-test




Shrinkage of the variance and moderated t-statistics Shrinkage of Standard Deviations




The data decides whether l_g

should be closer to $t_{g,pooled}$ or to t_g


Shrinkage of the variance with limma




Problems with ordinary t-test solved by moderated EB t-test



Problems with ordinary t-test solved by moderated EB t-test






treatD8

≺∂→

Experimental Design

Power?



$$\Delta = \bar{z}_{p1} - \bar{z}_{p2}$$
$$T_g = \frac{\Delta}{\sec \Delta}$$
$$T_g = \frac{\widehat{\text{signal}}}{\widehat{\text{Noise}}}$$

If we can assume equal variance in both treatment groups:

$$\operatorname{se}_{\Delta} = \operatorname{SD}_{\sqrt{\frac{1}{n_1} + \frac{1}{n_2}}}$$

 \rightarrow Design: if number of bio-repeats increases we have a higher power!

- Study on tamoxifen treated Estrogen Receptor (ER) positive breast cancer patients
- Proteomes for tumors of patients with good and poor outcome upon recurrence.
- Assess difference in power between 3vs3, 6vs6 and 9vs9 patients.

Experimental Design: Blocking

Sources of variability

$$\sigma^2 = \sigma_{bio}^2 + \sigma_{lab}^2 + \sigma_{extraction}^2 + \sigma_{run}^2 + \dots$$

- Biological: fluctuations in protein level between mice, fluctations in protein level between cells, ...
- Technical: cage effect, lab effect, week effect, plasma extraction, MS-run, ...

Blocking Example: mouse T-cells





Fig. 1. Label-free quantitative analysis of conventional and regulatory T cell proteomes. General analytical workflow based on cell sorting by flow cytometry using the DEREG mouse model and parallel proteomic analysis of Tconv and Treg cell populations by nanoLC-MS/MS and label-free relative quantification.

Blocking Example: mouse T-cells










Figure 2 | Blocking improves sensitivity by isolating variation in samples that is independent from treatment effects. (a) Measurements from treatment aliquots derived from different cell cultures are differentially offset (e.g., 1, 0.5, -0.5) because of differences in cultures. (b) When aliquots are derived from the same culture, measurements are uniformly offset (e.g., 0.5). (c) Incorporating blocking in data collection schemes. Repeats within blocks are considered technical replicates. In an incomplete block design, a block cannot accommodate all treatments.


Nature Methods 2014, 11(7) 699-700.

Blocking





Blocking



- \rightarrow All treatments of interest are present within block!
- $\rightarrow\,$ We can estimate the effect of the treatment within block!
- ightarrow We can isolate the between block variability from the analysis
- \rightarrow linear model:

$$y \sim type + mouse$$


 \rightarrow Not possible with Perseus!

Power gain of blocking


- Completely randomized design (CRD): 8 mice, 4 conventional T-cells, 4 regulatory T-cells.
- Randomized complete block desigh (RBC): 4 mice, for each mouse conventional and regulatory T-cells.

Power gain of blocking CRD

 $y \sim type$



$\begin{array}{l} \mathsf{RCB} \\ y \sim \mathsf{type} \end{array}$




statOmics, Ghent University lieven.clement@ugent.be

Anova table: P24452, Capg, Macrophage-capping protein

RCB design

	Df	Sum Sq	Mean Sq	F value	Pr(>F)	
type	1	15.2282	15.2282	3720.035	9.71e-06	***
mouse	3	0.2179	0.0726	17.747	0.02058	*
Residuals	3	0.0123	0.0041			



CRD design ### Df Sum Sq Mean Sq F value Pr(>F) type 1 11.6350 11.6350 122.86 3.211e-05 *** Residuals 6 0.5682 0.0947

Anova table: P24452, Capg, Macrophage-capping protein

RCB design ### Estimate Std. Error t value Pr(>|t|) (Intercept) 22.21485 0.05058 439.190 2.60e-08 *** 2.75937 0.04524 60.992 9.71e-06 *** typereg 0.30560 0.06398 4.776 0.0174 * mouse2 mouse3 -0.15193 0.06398 -2.375 0.0981 0.07331 0.06398 1.146 0.3350 mouse4 ___

Residual standard error: 0.06398 on 3 degrees of freedom

RCB design: no mouse effect
Estimate Std. Error t value Pr(>|t|)
(Intercept) 22.27160 0.09794 227.40 4.88e-13 ***
typereg 2.75937 0.13851 19.92 1.04e-06 ***
--Residual standard error: 0.1959 on 6 degrees of freedom

CRD design
CRD design ###
CRD design ###
Estimate Std. Error t value Pr(>|t|)
(Intercept) 23.3012 0.1557 149.65 6.00e-12 ***
typereg 2.4956 0.2251 11.08 3.21e-05 ***
--Residual standard error: 0.3077 on 6 degrees of freedom

Comparison residual variance

